MaxCyte acquires SeQure Dx for $4.5M cash; adds gene-editing safety assessment services

MAXCYTE, INC.

Initial consideration $4.5M in cash; up to $2.5M additional contingent on revenue targets.
SeQure reported ~$1.7M revenue and ~$6.5M loss (Jan–Nov 2024 unaudited); net assets $0.7M.
Acquisition expected to be accretive to MaxCyte's revenue growth; expands cell/gene therapy offerings.
SeQure specializes in on-target and off-target editing assessments for viral and non-viral modalities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.